Objective:To investigate the levels of serum thymidine kinase 1 (TK-1), FMS-like tyrosine kinase 3 ligand (Flt3L) and soluble CD30 (sCD30) at admission in patients with non-Hodgkin lymphoma (NHL), their correlations with various clinicopathological characteristics, and their predictive values for short-term prognosis.Methods:A prospective case series study was conducted. Sixty-five NHL patients who were admitted to Anyang District Hospital in Puyang City from February 2022 to February 2024 (NHL group) and 65 healthy individuals undergoing routine health examinations during the same period (healthy control group) were enrolled, and the serum levels of TK-1, Flt3L and sCD30 at admission were compared between the two groups. Serum levels of TK-1, Flt3L and sCD30 at admission were compared among NHL patients with varying clinicopathological characteristics, and Spearman correlation analysis was used to evaluate the relationships between these markers and clinicopathological characteristics. Patients were followed up for 6 months, the short-term prognosis was recorded and categorized as poor prognosis (relapse, metastasis or death) or good prognosis (survival without relapse or metastasis, and no further disease progression),and the serum levels of each marker at admission were compared between the two groups. Multivariate logistic regression models were employed to analyze the impact of serum levels of these markers at admission on short-term prognosis. Using follow-up records of prognosis status as the gold standard, receiver operating characteristic (ROC) curves were plotted to analyze the efficacy of individual and combined detection of serum TK-1, Flt3L and sCD30 at admission for predicting the short-term prognosis of patients.Results:At admission, the serum levels of TK-1 [(2.26±0.57) pmol/L
vs. (1.07±0.11) pmol/L], Flt3L [(84±5) pg/ml
vs. (61±8) pg/ml] and sCD30 [(150±11) kU/L
vs. (90±10) kU/L] in the NHL group were higher than those in the healthy control group, and the differences were statistical significant (all
P < 0.001). Among NHL patients, the serum levels of TK-1 [(2.51±0.55) pmol/L
vs. (2.05±0.45) pmol/L], Flt3L [(88±4) pg/ml
vs. (81±5) pg/ml] and sCD30 [(154±12) kU/L
vs. (145±10) kU/L] in patients with stage Ⅲ-Ⅳ were higher than those in patients with stage Ⅰ-Ⅱ, and the serum levels of TK-1 [(2.42±0.62) pmol/L
vs. (2.12±0.41) pmol/L], Flt3L [(86±5) pg/ml
vs. (83±5) pg/ml] and sCD30 [(157±11) kU/L
vs. (144±11) kU/L] in patients with poorly differentiation were higher than those in patients with intermediate or high differentiation, and the differences were statistically significant (all
P < 0.05). At admission, serum levels of TK-1 (
r = 0.60), Flt3L (
r = 0.63) and sCD30 (
r = 0.62) were positively correlated with pathological stage, whereas the levels of TK-1 (
r = -0.61), Flt3L (
r = -0.60) and sCD30 (
r = -0.63) were negatively correlated with the degree of differentiation, and the differences were statistical significance (all
P < 0.001). During a 6-month follow-up, 14 patients (21.5%) had poor prognosis, while 51 patients (78.5%) had good prognosis. At admission, the serum levels of TK-1 [(2.53±0.60) pmol/L
vs. (2.19±0.53) pmol/L], Flt3L [(90±4) pg/ml
vs. (83±6) pg/ml] and sCD30 [(158±10) kU/L
vs. (147±10) kU/L] in the poor prognosis group were higher than those in the good prognosis group, and the differences were statistically significant (all
P < 0.05). Multivariate logistic partial regression analysis revealed that elevated serum levels of TK-1 (
OR = 1.82, 95%
CI: 1.17-4.05,
P < 0.001), Flt3L (
OR = 1.89, 95%
CI: 1.14-3.12,
P < 0.001) and sCD30 (
OR = 1.95, 95%
CI: 1.03-3.70,
P < 0.001) at admission were independent risk factors for short-term poor prognosis in patients with NHL. ROC curve analysis indicated that, when assessed individually, the areas under the curve (AUC) for predicting short-term poor prognosis in NHL patients were 0.747 for TK-1, 0.734 for Flt3L, and 0.727 for sCD30. The combined predictive value of all three markers yielded an AUC of 0.926, with a sensitivity of 85.71% and a specificity of 88.24% at the optimal cutoff point.
Conclusions:At admission, serum levels of TK-1, Flt3L and sCD30 are elevated in patients with NHL compared with healthy individuals; these biomarker levels correlate with disease stage and tumor differentiation, and are further increased in patients with poor prognosis. Moreover, the combined detection of these three markers demonstrates good predictive accuracy for short-term prognosis in NHL patients.